(1) Background: African swine fever (ASF) is a highly contagious and fatal haemorrhagic disease in domestic pigs and wild boars, causing significant economic loss to the swine industry in the European Union. The genotype II of African swine fever has spread in many European countries since the virus was detected in 2007 in Georgia. In Poland, the genotype II of the ASF virus was confirmed on 17 February 2014 in the eastern part of the country and appeared to have been transmitted to Poland from Belarus.
View Article and Find Full Text PDFIntroduction: The molecular contamination of an animal facility was investigated during and after an infection with highly pathogenic African swine fever virus (ASFV) among domestic pigs. The investigation evaluated the risk of indirect transmission of the disease and indicated points that may facilitate cleaning and disinfection processes.
Material And Methods: Six domestic pigs were infected oronasally with the highly pathogenic Georgia 2007 strain.
African swine fever is a contagious disease, affecting pigs and wild boars, which poses a major threat to the pig industry worldwide and, therefore, to the agricultural economies of many countries. Despite intensive studies, an effective vaccine against the disease has not yet been developed. Since 2007, ASFV has been circulating in Eastern and Central Europe, covering an increasingly large area.
View Article and Find Full Text PDFAfrican swine fever remains one of the most economically important and dangerous diseases of the family. Until now, neither a safe vaccine nor a treatment against ASF has been available, which is why prevention of the disease involves biosecurity measures and early recognition based on accurate diagnosis. Nowadays, different strategies for ASF detection are discussed to reduce both animal suffering and the costs of ASF surveillance.
View Article and Find Full Text PDFIntroduction: African swine fever virus (ASFV) causes one of the most dangerous diseases of pigs and wild boar - African swine fever (ASF). Since its second introduction into Europe (in 2007), the disease has been spreading consistently, and now ASF-free European countries are at risk. Complex interactions between the host's immune system and the virus have long prevented the development of a safe vaccine against ASF.
View Article and Find Full Text PDF